Ripretinib is used for the treatment of advanced gastrointestinal stromal tumors (GIST) in patients who have received prior therapy with three or more kinase inhibitors, including imatinib. It functions as a broad-spectrum KIT and PDGFRα inhibitor, effectively targeting both primary and secondary mutations that drive tumor progression. Its unique switch-control inhibition mechanism allows it to suppress a wide range of resistant mutations that typically develop during earlier lines of therapy. Ripretinib is particularly valuable in late-line treatment settings, helping to prolong progression-free survival in patients with limited therapeutic options. It is taken orally, offering a convenient treatment option for patients with metastatic or unresectable GIST.